Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder

Author:

Talal Andrew H.1ORCID,Jaanimägi Urmo1,Dharia Arpan1,Dickerson Suzanne S.2

Affiliation:

1. Department of Medicine Jacobs School of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University at Buffalo Buffalo New York USA

2. School of Nursing, Division of Biobehavioral Health and Clinical Sciences, University at Buffalo Buffalo New York USA

Abstract

AbstractBackgroundPeople who use drugs (PWUD) frequently delay or avoid obtaining medical care in traditional healthcare settings. Through a randomized controlled trial, we investigated facilitated telemedicine for hepatitis C virus (HCV) integrated into opioid treatment programmes. We sought to understand the experiences and meanings of facilitated telemedicine and an HCV cure among PWUD.MethodsWe utilized purposive sampling to interview 25 participants, 6–40 months after achieving an HCV cure. We interpreted and explicated common meanings of participants' experiences of an HCV cure obtained through facilitated telemedicine.ResultsParticipants embraced facilitated telemedicine integrated into opioid treatment programmes as patient‐centred care delivered in ‘safe spaces’ (Theme 1). Participants elucidated their experiences of substance use and HCV while committing to treatment for both entities. Facilitated telemedicine integrated into opioid treatment programmes enabled participants to avoid stigma encountered in conventional healthcare settings (Theme 2). Participants conveyed facing negative perceptions of HCV and substance use disorder. Improved self‐awareness, acquired through HCV and substance use treatment, enabled participants to develop strategies to address shame and stigma (Theme 3). An HCV cure, considered by PWUD as a victory over a lethal infectious disease, promotes self‐confidence, enabling participants to improve their health and lives (Theme 4).ConclusionsIntegrating facilitated telemedicine into opioid treatment programmes addresses several healthcare barriers for PWUD. Similarly, obtaining an HCV cure increases their self‐confidence, permissive to positive lifestyle changes and mitigating the negative consequences of substance use.Patient and Public ContributionIn this study of patient involvement, we interviewed patient‐participants to understand the meaning of an HCV cure through facilitated telemedicine. Participants from a facilitated telemedicine pilot study provided essential input on the design and outcomes of a randomized controlled trial. Pilot study participants endorsed facilitated telemedicine in a testimonial video. They attended site initiation meetings to guide trial implementation. A Patient Advisory Committee (PAC) ensured that patient participants were active members of the research team. The PAC represented patients' voices through feedback on study procedures. A Sustainability Committee supported public involvement in the research process, including educational opportunities, feedback on implementation, and future sustainability considerations.

Funder

Patient-Centered Outcomes Research Institute

Publisher

Wiley

Subject

Public Health, Environmental and Occupational Health

Reference43 articles.

1. Age and generational patterns of overdose death risk from opioids and other drugs

2. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C

3. World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. 2016. Accessed May 24 2023.https://apps.who.int/iris/handle/10665/206453

4. US Department of Health and Human Services. Viral Hepatitis National Strategic Plan for the United States: a Roadmap to Elimination (2021–2025). 2020. Accessed January 19 2021. https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf

5. Accessible Hepatitis C Care for People Who Inject Drugs

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3